<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598348</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC006</org_study_id>
    <nct_id>NCT03598348</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer</brief_title>
  <official_title>Maintenance Treatment With Capecitabine Plus Apatinib vs. Apatinib and Observation After First-line XELOX/SOX Chemotherapy for Patients With Advanced Gastric Cancer: a Multicenter, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, controlled trial to evaluate the efficacy and safety of
      Maintenance Treatment with Capecitabine plus Apatinib, Apatinib and Observation after
      First-line XELOX/SOX chemotherapy for Patients with Advanced Gastric Cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Anticipated">October 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>36 months</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>From date of randomization until the date of first documented death from any cause, assessed up to 36 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Maintenance Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Treatment Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib+Capecitabine</intervention_name>
    <description>Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d</description>
    <arm_group_label>Maintenance Treatment Group A</arm_group_label>
    <other_name>apatinib</other_name>
    <other_name>capecitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 250mg po Qd</description>
    <arm_group_label>Maintenance Treatment Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 18-75；

          2. had histologically confirmed unresectable and/or metastatic (primary or recurrent)
             adenocarcinoma of the stomach or gastroesophageal junction；

          3. received 4-6 cycles of Xelox/SOX regimens as first-line chemotherapy and the response
             was not progression disease (PD);

          4. ECOG 0-2；

          5. Patients were tested for tumor HER2 status before treatment, and patients with
             HER2-negative disease；

          6. presence of at least one measurable lesion according to Response Evaluation Criteria
             in Solid Tumors (RECIST) version 1.1 guidelines；

          7. Subjects has to voluntarily join the study and sign the Informed Consent Form for the
             study;

          8. Adequate organ function as defined below: Hematologic ANC ≥ 2*109/L, Platelets ≥
             100*109/L, AST and ALT ≤ 2.5×ULN, TBIL ≤ 1.5×ULN

          9. Receiving no form of chemotherapy, targeted therapy or other study medication;

        Exclusion Criteria:

          1. previous radiotherapy to the abdomen；

          2. previous treatment for advanced disease (neoadjuvant chemotherapy was permitted if
             administered &gt;6 months before enrollment)；

          3. pregnant or lactating women or women of childbearing potential；

          4. disease progression during the first-line chemotherapy;

          5. active gastrointestinal bleeding, arterial thrombosis or cerebrovascular accident
             within 6 months before enrollment

          6. previous treatment of apatinib and Ramucirumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianglin Yuan, PhD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianglin Yuan, PhD,MD</last_name>
    <phone>8627-83663406</phone>
    <email>xlyuan1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Peng, PhD,MD</last_name>
    <phone>8627-83663407</phone>
    <email>pengpingtj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, PhD,MD</last_name>
      <phone>8627-83663406</phone>
      <email>xlyuan1020@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ping Peng, PhD,MD</last_name>
      <phone>8627-83663407</phone>
      <email>pengpingtj@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 15, 2018</last_update_submitted>
  <last_update_submitted_qc>July 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Professor, Chief physician</investigator_title>
  </responsible_party>
  <keyword>advanced gastric cancer, apatinib, capecitabine, maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

